Top

Published in:

01-07-2012 | Original Communication

The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature

Authors: M. Jallouli, D. Saadoun, B. Eymard, G. Leroux, J. Haroche, D. Le Thi Huong, C. De Gennes, C. Chapelon, O. Benveniste, B. Wechsler, P. Cacoub, Z. Amoura, J. C. Piette, N. Costedoat-Chalumeau

Published in: Journal of Neurology | Issue 7/2012

Abstract

The coexistence of systemic lupus erythematosus (SLE) and myasthenia gravis (MG) is rarely reported, and most of the published studies are case reports. Hydroxychloroquine, an antimalarial agent, is an essential treatment in patients with SLE but special caution is recommended when used in MG patients. We retrospectively analyzed the clinical features, laboratory findings, and outcome of 17 patients with both diseases with a special focus regarding hydroxychloroquine use and with a review of the literature. All patients were women. The mean age at MG onset and SLE diagnosis was 34.5 [14–64] and 37.8 [18–72] years, respectively. The presenting symptoms of MG were limb weakness (94%), ocular (88%) and bulbar involvement (53%). Autoantibodies against the acetylcholine receptor were positive in 94% of cases. The main manifestations of SLE included arthritis (88%), cytopenias (53%) and skin rash (41%). Treatment of SLE required hydroxychloroquine (94%), steroids (47%) and immunosuppressive drugs (18%). Among eight patients (47%) who developed MG after initiation of hydroxychloroquine, the question of induction of MG by hydroxychloroquine was raised in one patient. On the other hand, an exacerbation of myasthenic symptoms was only seen in one of the eight patients who received hydroxychloroquine after the diagnosis of MG. Including our cases, we reviewed a total of 70 patients with SLE and MG. Compared with a large series of 1,000 unselected SLE patients, those with associated MG were older, had lower incidence of cutaneous, renal, and neurological manifestations, and higher frequency of anticardiolipin antibodies and lupus anticoagulant. In conclusion, the clinical pattern of patients with SLE and MG seems to be characterized by a less severe course of SLE and higher frequency of antiphospholipid antibodies. Hydroxychloroquine treatment appears to be safe in this setting.

Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116(11):2843–2854PubMedCrossRef

Park MJ, Kim YA, Lee SS, Kim BC, Kim MK, Cho KH (2004) Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. J Korean Med Sci 19(1):134–136PubMedCrossRef

Costedoat-Chalumeau N, Amoura Z, Hulot JS, Lechat P, Piette JC (2007) Hydroxychloroquine in systemic lupus erythematosus. Lancet 369(9569):1257–1258PubMedCrossRef

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRef

LM Miyakis S, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannapoulos PG, Kritis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 4(2):295–306CrossRef

Bouchez B, Arnott G, Delandsheer E, Courteville-Delamarre V (1983) Association of myasthenia and disseminated lupus erythematosus. Review of the literature apropos of a case. LARC Med 3(8):541–549PubMed

Isaacs P (1971) Myasthenia with systemic lupus and palmoplantar keratosis. Br Med J 4(5783):339–340PubMedCrossRef

MacKechnie HL, Squires AH, Platts M, Pruzanski W (1973) Thymoma, myasthenia gravis, erythroblastopenic anemia and systemic lupus erythematosus in one patient. Can Med Assoc J 109(8):733–738PubMed

Saint-Faust M, Perelman S, Dupont D, Velin P, Chatel M (2010) Transient neonatal myasthenia gravis revealing a myasthenia gravis and a systemic lupus erythematosus in the mother: case report and review of the literature. Am J Perinatol 27(2):107–110PubMedCrossRef

10.

Gerli R, Paganelli R, Cossarizza A, Muscat C, Piccolo G, Barbieri D, Mariotti S, Monti D, Bistoni O, Raiola E, Venanzi FM, Bertotto A, Franceschi C (1999) Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol 103(5 Pt 1):865–872PubMedCrossRef

11.

Aarli JA, Milde EJ, Thunold S (1975) Arthritis in myasthenia gravis. J Neurol Neurosurg Psychiatry 38(11):1048–1055PubMedCrossRef

12.

Alarcon Segovia D, Galbraith RF, Maldonado JE, Howard FM Jr (1963) Systemic lupus erythematosus following thymectomy for myasthenia gravis. Report of two cases. Lancet 2(7309):662–665PubMedCrossRef

13.

Denney D, Rose RL (1961) Myasthenia gravis followed by systemic lupus erythematosus. A case report. Neurology 11:710–713PubMedCrossRef

14.

Kennes B, Delespesse G, Vandenbossche JL, Sternon J (1978) Systemic lupus erythematosus triggered by adult thymectomy in myasthenia gravis patient: report of a case. Acta Clin Belg 33(2):110–116PubMed

15.

Laukaitis JP, Borenstein DG (1989) Multiple autoimmune diseases in a predisposed patient. Arthritis Rheum 32(1):119–120PubMedCrossRef

16.

Mevorach D, Perrot S, Buchanan NM, Khamashta M, Laoussadi S, Hughes GR, Menkes CJ (1995) Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature. Lupus 4(1):33–37PubMedCrossRef

17.

Schoenen J, Delwaide PJ (1976) The association of myasthenia and disseminated lupus erythematosus. 2 cases. Nouv Presse Med 5(18):1185–1188PubMed

18.

Vaiopoulos G, Sfikakis PP, Kapsimali V, Boki K, Panayiotidis P, Aessopos A, Tsokos GC, Kaklamanis P (1994) The association of systemic lupus erythematosus and myasthenia gravis. Postgrad Med J 70(828):741–745PubMedCrossRef

19.

Mizon JP, Morcamp D, Lefebvre P, Froissart M, Guidicelli CP, Goasguen J (1979) Associated myasthenia and disseminated lupus erythematosus. A report on two cases and complete review of the published literature (author’s transl). Ann Med Interne (Paris) 130(11):489–500

20.

Abbruzzese G, Abbruzzese M, Bacigalupo A, Ratto S (1979) Systemic lupus erythematosus after thymectomy in a patient with myasthenia gravis. Neurology 29(10):1436–1437PubMedCrossRef

21.

Calabrese LH, Bach JF, Currie T, Vidt D, Clough J, Krakauer RS (1981) Development of systemic lupus erythematosus after thymectomy for myasthenia gravis. Studies of suppressor cell function. Arch Intern Med 141(2):253–255PubMedCrossRef

22.

Ciaccio M, Parodi A, Rebora A (1989) Myasthenia gravis and lupus erythematosus. Int J Dermatol 28(5):317–320PubMedCrossRef

23.

Le Loet X, Pouyol F, Lees O, Ducastelle T, Godin M, Deshayes P (1986) Acute systemic lupus erythematosus after thymectomy for myasthenia. Sequential study of lymphocyte subpopulations. Rev Med Interne 7(4):425–432PubMedCrossRef

24.

Sant SM (1997) Systemic lupus erythematosus after thymectomy in a patient with myasthenia gravis. Ir Med J 90(3):116–118PubMed

25.

Tellez-Zenteno JF, Remes-Troche JM, Mimenza-Alvarado A, Garcia-Ramos G, Estanol B, Vega-Boada F (2003) The association of myasthenia gravis and connective tissue diseases. Effects of thymectomy in six cases with rheumatoid arthritis and one case with systemic lupus erythematosus. Neurologia 18(2):54–58PubMed

26.

Omar HA, Alzahrani MA, Al Bshabshe AA, Assiri A, Shalaby M, Dwedar A, Abdulwahed SR, Hussein MR (2010) Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature. Clin Exp Nephrol 14(3):272–276

27.

Lee H, Chen W, Su K, Chou C, Tsai C (2008) Myasthenia gravis associated with lupus nephritis. Lupus 17(9):860–861PubMedCrossRef

28.

Iwadate H, Kobayashi H, Shio K, Noguchi E, Watanabe K, Sasajima T, Sekine H, Watanabe H, Ohira H, Obara K, Sato Y (2006) A case of systemic lupus erythematosus complicated by pure red cell aplasia and idiopathic portal hypertension after thymectomy. Mod Rheumatol 16(2):109–112PubMedCrossRef

29.

Grinlinton FM, Lynch NM, Hart HH (1991) A pair of monozygotic twins who are concordant for myasthenia gravis but became discordant for systemic lupus erythematosus post-thymectomy. Arthritis Rheum 34(7):916–919PubMedCrossRef

30.

Sthoeger Z, Neiman A, Elbirt D, Zinger H, Magen E, Burstein R, Eitan S, Abarbanel J, Mozes E (2006) High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am J Med Sci 331(1):4–9PubMedCrossRef

31.

Hrycek A (2009) A sequence of pathologic events in a patient after thymectomy for myasthenia gravis. Rheumatol Int [Epub ahead of print]

32.

Meloni F, Gueli N, Villatico Campbell S, Di Maio F, Di Bernardo MG, Di Nuzzo M, Carmenini G (1996) A case of systemic lupus erythematosus (SLE) and myasthenia gravis (MG). Allergy 51(5):362–363PubMed

33.

Branch CE Jr, Swift TR (1978) Systemic lupus erythematosus, myasthenia gravis, and Ehlers-Danlos syndrome. Ann Neurol 4(4):374–375PubMedCrossRef

34.

Chan MK, Britton M (1980) Comparative clinical features in patients with myasthenia gravis with systemic lupus erythematosus. J Rheumatol 7(6):838–842PubMed

35.

Killian PJ, Hoffman GS (1980) Coexistence of systemic lupus erythematosus and myasthenia gravis. South Med J 73(2):244–246PubMedCrossRef

36.

Valesini G, Pastore R, de Berardinis PG, Serafini U, Vincent A, Bottazzo GN (1983) Appearance of anti-acetylcholine receptor antibodies coincident with onset of myasthenic weakness in patient with systemic lupus erythematosus. Lancet 1(8328):831PubMedCrossRef

37.

Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ (1989) Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 80(4):290–295PubMedCrossRef

38.

Ben-Chetrit E, Pollack A, Flusser D, Rubinow A (1990) Coexistence of systemic lupus erythematosus and myasthenia gravis: two distinct populations of anti-DNA and anti-acetylcholine receptor antibodies. Clin Exp Rheumatol 8(1):71–74PubMed

39.

Barbosa RE, Cordova S, Cajigas JC (2000) Coexistence of systemic lupus erythematosus and myasthenia gravis. Lupus 9(2):156–157PubMedCrossRef

40.

Chaturvedi V, Handa R, Aggarwal P, Wali JP (2001) Systemic lupus erythematosus and myasthenia gravis. J Assoc Physicians India 49:670PubMed

41.

Bhinder S, Majithia V, Harisdangkul V (2006) Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidental-two case reports and review of the literature. Clin Rheumatol 25(4):555–556PubMedCrossRef

42.

Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore) 72(2):113–124

43.

Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475–490. pii:S1474-4422(09)70063-8PubMedCrossRef

44.

Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141–149PubMedCrossRef

45.

Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 998:413–423PubMedCrossRef

46.

Tsinzerling N, Lefvert AK, Matell G, Pirskanen-Matell R (2007) Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry 78(10):1109–1112PubMedCrossRef

47.

Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48(12):1246–1252PubMedCrossRef

48.

Oh SJ (2009) Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 5(2):53–64PubMedCrossRef

49.

(1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42(4):599–608

50.

Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, Moutsopoulos HM (2004) Sjogren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren’s syndrome. Arthritis Rheum 50(3):882–891PubMedCrossRef

51.

Xu D, Tian X, Zhang W, Zhang X, Liu B, Zhang F (2010) Sjogren’s syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case-control study. Lupus 19(2):197–200PubMedCrossRef

52.

Bagavant H, Thompson C, Ohno K, Setiady Y, Tung KS (2002) Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int Immunol 14(12):1397–1406PubMedCrossRef

53.

Bagavant H, Tung KS (2005) Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J Immunol 175(2):944–950PubMed

54.

Hang L, Theofilopoulos AN, Balderas RS, Francis SJ, Dixon FJ (1984) The effect of thymectomy on lupus-prone mice. J Immunol 132(4):1809–1813PubMed

55.

Steinberg AD, Law LD, Talal N (1970) The role of NZB-NZW F1 thymus in experimental tolerance and auto-immunity. Arthritis Rheum 13(4):369–377PubMedCrossRef

56.

Boonen A, Rennenberg R, van der Linden S (2000) Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature. Rheumatology (Oxford) 39(9):1044–1046CrossRef

57.

Bozzolo E, Bellone M, Quaroni N, Voci C, Sabbadini MG (2000) Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. Lupus 9(2):151–154PubMedCrossRef

58.

Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S (2005) Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105(2):735–741PubMedCrossRef

59.

Bonelli M, Smolen JS, Scheinecker C (2010) Treg and lupus. Ann Rheum Dis 69(Suppl 1):i65–i66PubMedCrossRef

60.

Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440PubMedCrossRef

61.

Schiffer L, Kumpers P, Davalos-Misslitz AM, Haubitz M, Haller H, Anders HJ, Witte T, Schiffer M (2009) B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant 24(12):3708–3712PubMedCrossRef

62.

Li LH, Li WX, Wu O, Zhang GQ, Pan HF, Li XP, Xu JH, Dai H, Ye DQ (2009) Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis. Mol Biol Rep 36(8):2047–2052PubMedCrossRef

63.

Moulian N, Bidault J, Truffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S (1997) Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 89(9):3287–3295PubMed

64.

Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27(12):2927–2931PubMed

65.

Robberecht W, Bednarik J, Bourgeois P, van Hees J, Carton H (1989) Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. Arch Neurol 46(4):464–468PubMedCrossRef

66.

Sghirlanzoni A, Mantegazza R, Mora M, Pareyson D, Cornelio F (1988) Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 11(2):114–119PubMedCrossRef

67.

Ritenour RJ, Cruess AF, Mishra AV (2008) Chloroquine-related myasthenic syndrome with severe retinopathy. Can J Ophthalmol 43(2):241–243PubMedCrossRef

68.

De Bleecker J, De Reuck J, Quatacker J, Meire F (1991) Persisting chloroquine-induced myasthenia? Acta Clin Belg 46(6):401–406PubMed

69.

Pichon P, Soichot P, Loche D, Chapelon M (1984) Myasthenic syndrome induced by chloroquine poisoning: an unusual clinical form confirmed by ocular involvement. Bull Soc Ophtalmol Fr 84 (2):219–222, 225

70.

Schumm F, Wietholter H, Fateh-Moghadam A (1981) Myasthenia syndrome during chloroquine treatment (author’s transl). Dtsch Med Wochenschr 106(51–52):1745–1747PubMedCrossRef

Title: The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature
Authors: M. Jallouli
D. Saadoun
B. Eymard
G. Leroux
J. Haroche
D. Le Thi Huong
C. De Gennes
C. Chapelon
O. Benveniste
B. Wechsler
P. Cacoub
Z. Amoura
J. C. Piette
N. Costedoat-Chalumeau
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 7/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-011-6335-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2012

Rating papilloedema: an evaluation of the Frisén classification in idiopathic intracranial hypertension

Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography

Transcranial magnetic stimulation in mild to severe hemiparesis early after stroke: a proof of principle and novel approach to improve motor function

Abnormal sensory-motor integration in a patient with anti-NMDA-receptor encephalitis

Progress in multiple sclerosis research in the last year

Falling too Fahr